| abstract |
An immunological composition for patients without HLA-A2 expression and an improved cancer therapy. An isolated or purified T having antigen specificity for a) melanoma antigen family A (MAGEA) -3 in relation to HLA-A1, or b) MAGE-A12 in relation to HLA-Cw7. A cell receptor (TCR) is provided. In addition, related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells and cell populations are provided. Also provided are antibodies related to TCR, or antigen-binding portions thereof, and pharmaceutical compositions. Further provided are a method for detecting the presence of cancer in a host and a method for treating or preventing cancer in a host. [Selection figure] None |